Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.

van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy V, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA, Kay EW, Hennessey BT, Verheul HMW, Gallagher WM, O'Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B.

J Clin Oncol. 2018 Jul 10;36(20):2052-2060. doi: 10.1200/JCO.2017.77.1782. Epub 2018 May 24.

PMID:
29792754
2.

BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.

Shields S, Conroy E, O'Grady T, McGoldrick A, Connor K, Ward MP, Useckaite Z, Dempsey E, Reilly R, Fan Y, Chubb A, Matallanas DG, Kay EW, O'Connor D, McCann A, Gallagher WM, Coppinger JA.

Oncotarget. 2018 Feb 28;9(21):15673-15690. doi: 10.18632/oncotarget.24590. eCollection 2018 Mar 20.

3.

Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.

O'Brien KP, Khan S, Gilligan KE, Zafar H, Lalor P, Glynn C, O'Flatharta C, Ingoldsby H, Dockery P, De Bhulbh A, Schweber JR, St John K, Leahy M, Murphy JM, Gallagher WM, O'Brien T, Kerin MJ, Dwyer RM.

Oncogene. 2018 Apr;37(16):2137-2149. doi: 10.1038/s41388-017-0116-9. Epub 2018 Jan 25.

PMID:
29367765
4.

Epigenetics of malignant melanoma.

Moran B, Silva R, Perry AS, Gallagher WM.

Semin Cancer Biol. 2017 Oct 23. pii: S1044-579X(17)30130-X. doi: 10.1016/j.semcancer.2017.10.006. [Epub ahead of print] Review.

PMID:
29074395
5.

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.

Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O'Donovan N, O'Connor D, Gallagher WM, Crown J, Fersht AR, Duffy MJ.

Cancer Lett. 2018 Feb 1;414:99-106. doi: 10.1016/j.canlet.2017.09.053. Epub 2017 Oct 22.

PMID:
29069577
6.

Absolute Quantification of Toxicological Biomarkers via Mass Spectrometry.

Lau TYK, Collins BC, Stone P, Tang N, Gallagher WM, Pennington SR.

Methods Mol Biol. 2017;1641:337-348. doi: 10.1007/978-1-4939-7172-5_19.

PMID:
28748474
7.

Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.

Moran B, Das S, Smeets D, Peutman G, Klinger R, Fender B, Connor K, Ebert M, Gaiser T, Prehn JH, Bacon O, Kay E, Hennessy B, Murphy V, Ylstra B, Lambrechts D, Byrne AT, Gallagher WM, O'Connor DP.

Oncotarget. 2017 Jul 18;8(29):48126-48137. doi: 10.18632/oncotarget.18296.

8.

Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma.

Wouters J, Vizoso M, Martinez-Cardus A, Carmona FJ, Govaere O, Laguna T, Joseph J, Dynoodt P, Aura C, Foth M, Cloots R, van den Hurk K, Balint B, Murphy IG, McDermott EW, Sheahan K, Jirström K, Nodin B, Mallya-Udupi G, van den Oord JJ, Gallagher WM, Esteller M.

BMC Med. 2017 Jun 5;15(1):101. doi: 10.1186/s12916-017-0851-3.

9.

Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.

Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R.

Oncotarget. 2017 Jun 27;8(26):42949-42961. doi: 10.18632/oncotarget.17306.

10.

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

Li B, Ni Chonghaile T, Fan Y, Madden SF, Klinger R, O'Connor AE, Walsh L, O'Hurley G, Mallya Udupi G, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn S, Jirstrom K, Caldas C, O'Connor DP, Gallagher WM.

Cancer Res. 2017 Jul 15;77(14):3834-3845. doi: 10.1158/0008-5472.CAN-16-2546. Epub 2017 Apr 28.

PMID:
28455421
11.

Master Transcriptional Regulators in Cancer: Discovery via Reverse Engineering Approaches and Subsequent Validation.

Moran B, Rahman A, Palonen K, Lanigan FT, Gallagher WM.

Cancer Res. 2017 May 1;77(9):2186-2190. doi: 10.1158/0008-5472.CAN-16-1813. Epub 2017 Apr 20. Review.

12.

The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways.

Dwane L, Gallagher WM, Ní Chonghaile T, O'Connor DP.

J Biol Chem. 2017 Mar 3;292(9):3543-3551. doi: 10.1074/jbc.R116.755694. Epub 2017 Feb 1. Review.

13.

A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.

O'Farrell AC, Evans R, Silvola JM, Miller IS, Conroy E, Hector S, Cary M, Murray DW, Jarzabek MA, Maratha A, Alamanou M, Udupi GM, Shiels L, Pallaud C, Saraste A, Liljenbäck H, Jauhiainen M, Oikonen V, Ducret A, Cutler P, McAuliffe FM, Rousseau JA, Lecomte R, Gascon S, Arany Z, Ky B, Force T, Knuuti J, Gallagher WM, Roivainen A, Byrne AT.

PLoS One. 2017 Jan 27;12(1):e0169964. doi: 10.1371/journal.pone.0169964. eCollection 2017.

14.

Circulating MicroRNAs in Cancer.

O'Brien KP, Ramphul E, Howard L, Gallagher WM, Malone C, Kerin MJ, Dwyer RM.

Methods Mol Biol. 2017;1509:123-139.

PMID:
27826923
15.

Assessment of Significance of Novel Proteins in Breast Cancer Using Tissue Microarray Technology.

Mulrane L, Gallagher WM, O'Connor DP.

Methods Mol Biol. 2017;1501:311-325.

PMID:
27796961
16.

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.

Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ.

Oncotarget. 2016 Nov 15;7(46):75518-75525. doi: 10.18632/oncotarget.12782.

17.

Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.

Murphy AG, Casey R, Maguire A, Tosetto M, Butler CT, Conroy E, Reynolds AL, Sheahan K, O'Donoghue D, Gallagher WM, Fennelly D, Kennedy BN, O'Sullivan J.

Sci Rep. 2016 Oct 14;6:34523. doi: 10.1038/srep34523.

18.

Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer.

Burke L, Butler CT, Murphy A, Moran B, Gallagher WM, O'Sullivan J, Kennedy BN.

Front Cell Dev Biol. 2016 Sep 21;4:103. eCollection 2016. Review.

19.

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J, Duffy MJ.

Int J Cancer. 2017 Jan 1;140(1):234-246. doi: 10.1002/ijc.30425. Epub 2016 Sep 24.

20.

De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.

Smith A, Murphy L, Sharp L, O'Connor D, Gallagher WM, Bennett K, Barron TI.

Br J Cancer. 2016 Aug 23;115(5):592-8. doi: 10.1038/bjc.2016.232. Epub 2016 Aug 2.

21.

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, Young L, Kay EW, O'Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT.

J Natl Cancer Inst. 2016 Jul 4;108(8). pii: djw111. doi: 10.1093/jnci/djw111. Print 2016 Aug. No abstract available.

22.

Functionalization of emissive conjugated polymer nanoparticles by coprecipitation: consequences for particle photophysics and colloidal properties.

Singh A, Bezuidenhout M, Walsh N, Beirne J, Felletti R, Wang S, Fitzgerald KT, Gallagher WM, Kiely P, Redmond G.

Nanotechnology. 2016 Jul 29;27(30):305603. doi: 10.1088/0957-4484/27/30/305603. Epub 2016 Jun 16.

PMID:
27306338
23.

Lysosome triggered near-infrared fluorescence imaging of cellular trafficking processes in real time.

Grossi M, Morgunova M, Cheung S, Scholz D, Conroy E, Terrile M, Panarella A, Simpson JC, Gallagher WM, O'Shea DF.

Nat Commun. 2016 Mar 1;7:10855. doi: 10.1038/ncomms10855.

24.

Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.

Walsh L, Gallagher WM, O'Connor DP, Ní Chonghaile T.

Expert Rev Mol Diagn. 2016;16(5):541-51. doi: 10.1586/14737159.2016.1156534. Epub 2016 Mar 16. Review.

PMID:
26895288
25.

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR, Gaber A, O'Hurley G, Lehn S, Muris JJ, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O'Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirström K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R.

Sci Rep. 2016 Jan 5;6:18517. doi: 10.1038/srep18517.

26.

Prognostic and predictive biomarkers in melanoma: an update.

Foth M, Wouters J, de Chaumont C, Dynoodt P, Gallagher WM.

Expert Rev Mol Diagn. 2016;16(2):223-37. doi: 10.1586/14737159.2016.1126511. Epub 2015 Dec 22. Review.

PMID:
26620320
27.

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.

O'Callaghan DS, Rexhepaj E, Gately K, Coate L, Delaney D, O'Donnell DM, Kay E, O'Connell F, Gallagher WM, O'Byrne KJ.

Eur Respir J. 2015 Dec;46(6):1762-72. doi: 10.1183/13993003.00176-2014. Epub 2015 Nov 5.

28.

The Role of Exosomes in Breast Cancer.

Lowry MC, Gallagher WM, O'Driscoll L.

Clin Chem. 2015 Dec;61(12):1457-65. doi: 10.1373/clinchem.2015.240028. Epub 2015 Oct 14. Review.

29.

miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.

O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O'Driscoll L.

Oncotarget. 2015 Oct 20;6(32):32774-89. doi: 10.18632/oncotarget.5192.

30.

Relationship between serum response factor and androgen receptor in prostate cancer.

Prencipe M, O'Neill A, O'Hurley G, Nguyen LK, Fabre A, Bjartell A, Gallagher WM, Morrissey C, Kay EW, Watson RW.

Prostate. 2015 Nov;75(15):1704-17. doi: 10.1002/pros.23051. Epub 2015 Aug 7.

31.

Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer.

O'Hurley G, Busch C, Fagerberg L, Hallström BM, Stadler C, Tolf A, Lundberg E, Schwenk JM, Jirström K, Bjartell A, Gallagher WM, Uhlén M, Pontén F.

PLoS One. 2015 Aug 3;10(8):e0133449. doi: 10.1371/journal.pone.0133449. eCollection 2015.

32.

Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients.

Lanigan F, Brien GL, Fan Y, Madden SF, Jerman E, Maratha A, Aloraifi F, Hokamp K, Dunne EJ, Lohan AJ, Flanagan L, Garbe JC, Stampfer MR, Fridberg M, Jirstrom K, Quinn CM, Loftus B, Gallagher WM, Geraghty J, Bracken AP.

FEBS J. 2015 Sep;282(18):3455-73. doi: 10.1111/febs.13354. Epub 2015 Jul 14.

33.

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M.

Nat Med. 2015 Jul;21(7):741-50. doi: 10.1038/nm.3863. Epub 2015 Jun 1.

34.

FKBPL: a marker of good prognosis in breast cancer.

Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T.

Oncotarget. 2015 May 20;6(14):12209-23.

35.

The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides.

Szwej E, Devocelle M, Kenny S, Guzik M, O'Connor S, Nikodinovic-Runic J, Radivojevic J, Maslak V, Byrne AT, Gallagher WM, Zulian QR, Zinn M, O'Connor KE.

J Biotechnol. 2015 Jun 20;204:7-12. doi: 10.1016/j.jbiotec.2015.02.036. Epub 2015 Mar 24.

PMID:
25820126
36.

Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies.

Mischak H, Critselis E, Hanash S, Gallagher WM, Vlahou A, Ioannidis JP.

Am J Epidemiol. 2015 May 1;181(9):635-47. doi: 10.1093/aje/kwu462. Epub 2015 Mar 19. Review.

PMID:
25792606
37.

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM.

Melanoma Res. 2015 Jun;25(3):189-99. doi: 10.1097/CMR.0000000000000149.

PMID:
25746038
38.

Commercialized biomarkers: new horizons in prostate cancer diagnostics.

Murphy L, Prencipe M, Gallagher WM, Watson RW.

Expert Rev Mol Diagn. 2015 Apr;15(4):491-503. doi: 10.1586/14737159.2015.1011622. Epub 2015 Feb 24. Review.

PMID:
25711191
39.

p53 as a target for the treatment of cancer.

Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM.

Cancer Treat Rev. 2014 Dec;40(10):1153-60. doi: 10.1016/j.ctrv.2014.10.004. Review.

PMID:
25455730
40.

Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.

Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT.

Br J Cancer. 2014 Dec 9;111(12):2275-86. doi: 10.1038/bjc.2014.529. Epub 2014 Nov 6.

41.

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.

Madden SF, Clarke C, Stordal B, Carey MS, Broaddus R, Gallagher WM, Crown J, Mills GB, Hennessy BT.

Mol Cancer. 2014 Oct 24;13:241. doi: 10.1186/1476-4598-13-241.

42.

Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer.

O'Leary PC, Terrile M, Bajor M, Gaj P, Hennessy BT, Mills GB, Zagozdzon A, O'Connor DP, Brennan DJ, Connor K, Li J, Gonzalez-Angulo AM, Sun HD, Pu JX, Pontén F, Uhlén M, Jirström K, Nowis DA, Crown JP, Zagozdzon R, Gallagher WM.

Breast Cancer Res. 2014 Jul 10;16(4):R79. doi: 10.1186/bcr3691.

43.

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.

Denecker G, Vandamme N, Akay O, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, Udupi GM, Rafferty M, Balint B, Gallagher WM, Ghanem G, Huylebroeck D, Haigh J, van den Oord J, Larue L, Davidson I, Marine JC, Berx G.

Cell Death Differ. 2014 Aug;21(8):1250-61. doi: 10.1038/cdd.2014.44. Epub 2014 Apr 25.

44.

Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers.

O'Hurley G, Sjöstedt E, Rahman A, Li B, Kampf C, Pontén F, Gallagher WM, Lindskog C.

Mol Oncol. 2014 Jun;8(4):783-98. doi: 10.1016/j.molonc.2014.03.008. Epub 2014 Mar 21. Review.

45.

microRNAs: a new class of breast cancer biomarkers.

Mulrane L, Klinger R, McGee SF, Gallagher WM, O'Connor DP.

Expert Rev Mol Diagn. 2014 Apr;14(3):347-63. doi: 10.1586/14737159.2014.901153. Review.

PMID:
24649821
46.

A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer.

Mulrane L, Gallagher WM, O'Connor DP.

Breast Cancer Res. 2014 Nov 18;16(6):467. doi: 10.1186/s13058-014-0467-x.

47.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

48.

MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach.

Nyamundanda G, Gormley IC, Fan Y, Gallagher WM, Brennan L.

BMC Bioinformatics. 2013 Nov 21;14:338. doi: 10.1186/1471-2105-14-338.

49.

The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.

O'Hurley G, Prencipe M, Lundon D, O'Neill A, Boyce S, O'Grady A, Gallagher WM, Morrissey C, Kay EW, Watson RW.

Prostate. 2014 Feb;74(3):306-13. doi: 10.1002/pros.22752.

PMID:
24249383
50.

miRNA dysregulation in breast cancer.

Mulrane L, McGee SF, Gallagher WM, O'Connor DP.

Cancer Res. 2013 Nov 15;73(22):6554-62. doi: 10.1158/0008-5472.CAN-13-1841. Epub 2013 Nov 7. Review.

Supplemental Content

Loading ...
Support Center